Postdoctoral Research Associate St. John's University Queens, New York
Pulmonary fibrosis is a chronic and progressive lung disorder characterized by excessive deposition of fibrous tissue, leading to impaired lung function and respiratory failure. These complications have emerged as severe outcomes in COVID-19-affected patients and effective treatment options are urgently needed. Traditional treatment for pulmonary fibrosis are limited and often ineffective due to the intricate pathophysiology of pulmonary organs. However, the emergence of FAP inhibitor-enabled nano theranostics provides a promising new-age approach for treating this debilitating condition. FAP inhibitor-enabled inhalable nano theranostics involve use of inhalable nanoparticles containing fibroblast activation protein (FAP) inhibitors for targeted delivery and image-guided therapy in pulmonary fibrosis. These theranostic nanoparticles not only inhibit the activity of FAP, a key enzyme involved in fibrotic processes but also serve as diagnostic tools for monitoring disease progression and response to treatment. Overall, inhalable nanotheranostics is an innovative and relevant approach for treating pulmonary fibrosis, including COVID-19-related fibrotic complications.
Learning Objectives:
Learn about current challenges in therapeutics for fibrotic disorders, and techniques associated with the design of FAP inhibitor-enabled inhalable nanotheranostics for targeted drug delivery in pulmonary organs.
Learn about the the therapeutic potential offered by FAPinhibitors
Learn about the conjugation of FAPinhibitors with nano theranostics for multifunctional and targeted drug delivery approach